Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v2.3.0.15
Consolidated Balance Sheets (USD $)
Sep. 30, 2011
Mar. 31, 2011
ASSETS    
Cash $ 45,579 $ 15,704
Deferred financing costs 110,193 157,732
Note receivable   200,000
Interest receivable   7,096
Prepaid expenses and other current assets 18,413 29,711
Total current assets 174,185 410,243
Property and equipment, net 4,329 7,785
Patents and patents pending, net 135,399 139,981
Deposits 9,210 9,210
Total assets 323,123 567,219
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Accounts payable 410,655 308,413
Due to related parties 617,570 617,570
Notes payable 594,796 190,000
Convertible notes payable, net of discounts 2,335,044 2,181,852
Derivative liabilities 1,341,726 2,002,896
Accrued liquidated damages 437,800 437,800
Other current liabilities 924,521 804,386
Total current liabilities 6,662,112 6,542,917
Commitments and Contingencies (Note 12)    
Common stock, par value $0.001 per share; 250,000,000 shares authorized as of September 30, 2011 and March 31, 2011; 100,995,917 and 77,467,361 shares issued and outstanding as of September 30, 2011 and March 31, 2011, respectively 100,998 77,469
Additional paid-in capital 45,071,336 42,418,778
Deficit accumulated during development stage (51,511,323) (48,471,945)
Total stockholders’ deficit (6,338,989) (5,975,698)
Total liabilities and stockholders' deficit $ 323,123 $ 567,219